DTX311

DTX311 is a **nanomedicine program from Dome Therapeutics** based on next-generation polymeric nanoparticles designed for brain-targeted delivery. For the Alzheimer's disease program, Dome's public materials identify the asset as a preclinical or discovery-stage candidate, but do not disclose the specific therapeutic payload, molecular target, route of administration, or detailed mechanism beyond a nanoparticle-based approach intended to reach brain cell populations. The platform is described as originating from Johns Hopkins University research and is part of a broader DTX311 franchise spanning central nervous system indications including glioblastoma, medulloblastoma, and Alzheimer's disease.